Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Christopher Christiani, M.D.

Co-Author

This page shows the publications co-authored by David Christiani and Rebecca Heist.
Connection Strength

4.919
  1. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics. 2009 Jan; 10(1):59-68.
    View in: PubMed
    Score: 0.411
  2. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol. 2008 Dec 01; 26(34):5596-602.
    View in: PubMed
    Score: 0.406
  3. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008 Feb 20; 26(6):856-62.
    View in: PubMed
    Score: 0.387
  4. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol. 2007 Jun 01; 25(16):2243-7.
    View in: PubMed
    Score: 0.369
  5. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res. 2006 Sep 15; 12(18):5448-53.
    View in: PubMed
    Score: 0.351
  6. Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2503-11.
    View in: PubMed
    Score: 0.152
  7. Invasive adenocarcinoma of the lung is associated with the upper lung regions. Lung Cancer. 2014 May; 84(2):145-50.
    View in: PubMed
    Score: 0.147
  8. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012 Dec; 7(12):1775-1780.
    View in: PubMed
    Score: 0.135
  9. A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer. 2012 Jul 15; 118(14):3654-65.
    View in: PubMed
    Score: 0.126
  10. Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16345-50.
    View in: PubMed
    Score: 0.124
  11. Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer. PLoS One. 2011; 6(8):e22961.
    View in: PubMed
    Score: 0.123
  12. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study. Cancer. 2012 Feb 01; 118(3):804-11.
    View in: PubMed
    Score: 0.123
  13. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia. 2011 Apr; 13(4):386-92.
    View in: PubMed
    Score: 0.120
  14. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis. 2011 Apr; 32(4):502-6.
    View in: PubMed
    Score: 0.118
  15. A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis. 2010 Jul; 31(7):1259-63.
    View in: PubMed
    Score: 0.113
  16. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol. 2010 May 10; 28(14):2445-51.
    View in: PubMed
    Score: 0.112
  17. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2009 Jun 01; 27(16):2660-7.
    View in: PubMed
    Score: 0.105
  18. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus. 2010 Jan; 23(1):36-9.
    View in: PubMed
    Score: 0.104
  19. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008 Dec; 29(12):2330-4.
    View in: PubMed
    Score: 0.101
  20. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis. 2008 Nov; 29(11):2147-52.
    View in: PubMed
    Score: 0.100
  21. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer. 2008 Feb 15; 122(4):915-8.
    View in: PubMed
    Score: 0.097
  22. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008 Jan 15; 14(2):612-7.
    View in: PubMed
    Score: 0.096
  23. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008 Apr; 8(2):129-38.
    View in: PubMed
    Score: 0.091
  24. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007 Feb 10; 25(5):479-85.
    View in: PubMed
    Score: 0.090
  25. Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients. Clin Cancer Res. 2006 Dec 01; 12(23):7187-93.
    View in: PubMed
    Score: 0.089
  26. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2239-45.
    View in: PubMed
    Score: 0.089
  27. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer. 2006 Sep; 53(3):375-80.
    View in: PubMed
    Score: 0.086
  28. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. Cancer Epidemiol. 2017 04; 47:28-34.
    View in: PubMed
    Score: 0.045
  29. Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369.
    View in: PubMed
    Score: 0.037
  30. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. J Gastroenterol Hepatol. 2013 Sep; 28(9):1482-8.
    View in: PubMed
    Score: 0.036
  31. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2012 Oct 01; 18(19):5507-14.
    View in: PubMed
    Score: 0.033
  32. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer. 2012 Dec 01; 131(11):2478-86.
    View in: PubMed
    Score: 0.032
  33. Association of the MDM2 T309G polymorphism and gastroesophageal reflux disease (GERD) with overall survival (OS) in esophageal adenocarcinoma (EAC). J Clin Oncol. 2011 May 20; 29(15_suppl):10595.
    View in: PubMed
    Score: 0.030
  34. Early adulthood obesity, cumulative smoking, and esophageal cancer survival. J Clin Oncol. 2011 May 20; 29(15_suppl):1546.
    View in: PubMed
    Score: 0.030
  35. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011 Jun; 72(3):370-7.
    View in: PubMed
    Score: 0.029
  36. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009 Aug; 19(8):613-25.
    View in: PubMed
    Score: 0.027
  37. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res. 2009 Jul 15; 15(14):4680-5.
    View in: PubMed
    Score: 0.027
  38. Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis. 2009 Aug; 30(8):1363-7.
    View in: PubMed
    Score: 0.027
  39. Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk. J Clin Oncol. 2009 May 20; 27(15_suppl):11029.
    View in: PubMed
    Score: 0.026
  40. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res. 2009 May 01; 15(9):3103-9.
    View in: PubMed
    Score: 0.026
  41. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 2009 May; 30(5):793-8.
    View in: PubMed
    Score: 0.026
  42. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res. 2008 Jun 15; 14(12):4010-5.
    View in: PubMed
    Score: 0.025
  43. p53 Arg72Pro, MDM2 T309G, CCND1 G870A polymorphisms, histology and esophageal cancer prognosis. J Clin Oncol. 2008 May 20; 26(15_suppl):11033.
    View in: PubMed
    Score: 0.025
  44. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control. 2008 Dec; 19(10):1077-83.
    View in: PubMed
    Score: 0.025
  45. Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma. Br J Cancer. 2008 Feb 26; 98(4):689-92.
    View in: PubMed
    Score: 0.024
  46. A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):204-11.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.